目的糖尿病腎病（diabetic nephropathy,DN）是糖尿病嚴(yán)重的慢性微血管并發(fā)癥之一,根據(jù)中國腎臟病監(jiān)控網(wǎng)絡(luò)（China Kidney Disease Network,CK-NET）2019年發(fā)布的《中國腎臟病年度報(bào)告》數(shù)據(jù)顯示,糖尿病腎病已超過腎小球腎炎,成為慢性腎臟�。╟hronic kidney disease,CKD）的首位病因,占總體病因的27.0%。糖尿病腎病是一個(gè)異質(zhì)性的疾病,目前的治療策略包括嚴(yán)格的血糖、血壓、血脂控制等多危險(xiǎn)因素干預(yù)療法。自從1994年腎素-血管緊張素系統(tǒng)抑制劑（renin angiotensin system inhibitor,RASI）卡托普利可以降低1型糖尿病患者的蛋白尿,2004年發(fā)現(xiàn)氯沙坦可以降低2型糖尿病患者的蛋白尿,保護(hù)腎功能外,沒有其他藥物證明可以降低糖尿病腎臟疾病的進(jìn)展。直到2019年,Credence（Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation）研究發(fā)現(xiàn)卡格列凈可以顯著減少2型糖... 

【文章來源】：中國醫(yī)科大學(xué)遼寧省

【文章頁數(shù)】：53 頁

【學(xué)位級別】：碩士

【文章目錄】：
中文摘要
Abstract
Abbreviations
1 Introduction
2 Materials and Methods
    2.1 Cell culture and Treatment of Proximal Renal Tubular Epithelial cells
    2.2 Western blot
    2.3 Measurement of Cell Proliferation
    2.4 Statistical analysis
3 Results
    3.1 Effect of Empagliflozin on HIF-1αand Glucose Transporter-1
    3.2 Effect of Empagliflozin on Sodium Glucose Co-Transporter2
    3.3 Effect of Hyperglycemia on Profibrotic Proteins
    3.4 Anti-fibrotic effect of Empagliflozin
    3.5 Anti-epithelial mesenchymal transition(EMT)effect of Empagliflozin
    3.6 The anti-Proliferative Effect of Empagliflozin on HK-2 cell line
4 Discussion
5 Conclusion
    5.1 Study Limitations
    5.2 Competing interest
    5.3 Self evaluation of Innovation in this study
References
Review
    References
Research achievements during the course of study
Thanks
Biography



本文編號：3614927